Skip to main content
Contact
Login
Our Company
Our Company
Mission
Leadership
Clinical Studies
Clinical Studies
ECLIPSE
GRECO-Breast Cancer
Solutions
Solutions
Treatment Selection
Residual Disease & Recurrence Monitoring
Early Detection
Biopharma Solutions
International
Investors
Investors
Media
Media
Press Releases
Resources and Media Assets
Contacts
Careers
Careers
Join Our Mission
Jobs
Press Releases
Investors Menu
Home
Press Releases
Events & Presentations
Events
Presentations
Stock Information
Stock Quote & Chart
Analyst Coverage
Financials
Quarterly Results
Annual Reports
SEC Filings
Corporate Governance
Governance Documents
Leadership
Board of Directors
Committee Composition
Resources
Investor FAQs
Investor Email Alerts
Investor Contacts
Normal
Press Release RSS Feed (opens in new window)
Press release year list
2022
2021
2020
2019
2018
2017
December 1, 2022
Guardant Health to Showcase New Data at San Antonio Breast Cancer Symposium 2022 Demonstrating Utility of Its Blood Tests for Advanced-stage Breast Cancer Patients
November 3, 2022
Guardant Health Reports Third Quarter 2022 Financial Results
October 10, 2022
Guardant Health to Report Third Quarter 2022 Financial Results on November 3, 2022
September 9, 2022
Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner
September 6, 2022
Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients
August 31, 2022
Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology Therapeutics
August 29, 2022
Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference
August 15, 2022
Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers
August 12, 2022
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations
August 8, 2022
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference
August 8, 2022
Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer
August 5, 2022
Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer
August 4, 2022
Guardant Health Reports Second Quarter 2022 Financial Results
August 2, 2022
Guardant Health Receives Medicare Coverage for Guardant Reveal™ Test
July 13, 2022
Guardant Health to Report Second Quarter 2022 Financial Results on August 4, 2022
July 7, 2022
Steve E. Krognes Joins Guardant Health Board of Directors
June 13, 2022
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
May 26, 2022
Guardant Health to Participate in Upcoming June Investor Conferences
May 25, 2022
First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d’Hebron Institute of Oncology
May 23, 2022
Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 21, 2022
Guardant Health Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-of-its Kind Prospective Study at Digestive Disease Week 2022
May 5, 2022
Guardant Health Reports First Quarter 2022 Financial Results
May 2, 2022
Guardant Health Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults
April 28, 2022
Guardant Health to Participate in the BofA Securities 2022 Healthcare Conference
April 13, 2022
Guardant Health to Report First Quarter Financial Results on May 5, 2022
April 11, 2022
Guardant Health Presents New Data Showing Blood Test Highly Accurate in Detecting Multiple Cancers at the American Association for Cancer Research Annual Meeting
April 4, 2022
Guardant Health Announces Partnership with Epic to Streamline Access to Company’s Broad Portfolio of Cancer Tests
March 17, 2022
Guardant Health Response to Frivolous and Retaliatory Lawsuit Filed by Illumina
March 14, 2022
Guardant Health Receives Regulatory Approval for Guardant360® CDx in Japan
March 9, 2022
Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at the American Association for Cancer Research Annual Meeting
March 8, 2022
Guardant Health Receives Medicare Coverage for Guardant360 TissueNext™ Test
February 23, 2022
Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook
February 7, 2022
Guardant Health to Participate in Upcoming Investor Conferences
February 1, 2022
Guardant Health to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
January 19, 2022
Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium
January 18, 2022
Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults
January 7, 2022
Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation